Inhibition of mTORC1 by rapamycin results in feedback activation of AktS473 and aggravates hallmarks of osteoarthritis in female mice and non-human primates
Paper summary: https://www.biorxiv.org/content/10.1101/2024.05.14.594256v2
Full PDF: https://www.biorxiv.org/content/10.1101/2024.05.14.594256v2.full.pdf
I hadn’t seen this posted here. All I found is a 202 thread saying that Rapa delays osteoarthritis (Rapamycin Delays Age-related Osteoarthritis)
I think the study abstract says everything you need to know, so I just copy-paste it here:
ABSTRACT
Purpose: Genetic deletion of mTOR has protected against post-traumatic osteoarthritis (OA) in
male mice, however, effects of pharmacological mTOR-inhibition are equivocal and have not been
tested in aging models nor in female subjects. Therefore, the goal of this study was to determine
if mTOR-inhibition by rapamycin can modify OA pathology in aging non-human primates and
female mice.
Methods: Common marmosets were administered oral rapamycin (1mg/kg/day) or vehicle starting near mid-life until death. Five-month-old, female C57BL/6J mice were treated with vehicle or
rapamycin (IP, 2mg/kg, 3x/week) for 8-weeks following non-invasive ACL rupture. Knee OA
pathology was assessed via microCT and histology. Phosphorylation of mTORC1 (p-RPS6S235/36)
and mTORC2 (p-AktS473, p-NDRG1T638, p-PKCαT348) substrates were evaluated via western blot
in articular cartilage, meniscus, and/or infrapatellar fat pad. ATDC5 cells were cultured with
rapamycin to determine time and dose effects on mTORC1/2 signaling.
Results: In marmosets, rapamycin did not impact age-related radiographic OA severity or
cartilage pathology but increased medial meniscus calcification and lowered lateral tibia
subchondral thickness, particularly in females. In female mice, rapamycin worsened ACLR-
induced meniscus calcification and cartilage pathology. In marmoset and mouse joint tissues,
rapamycin inhibited mTORC1 and increased p-AktS473 but not p-NDRG1T638 or p-PKCαT348
This mTOR signaling pattern was replicated in ATDC5 cells during exposure to low concentrations of
rapamycin.
Conclusions: Rapamycin attenuated mTORC1 signaling with feedback activation of AktS473 in
articular cartilage, meniscus, and/or infrapatellar fat pad and was accompanied by deleterious
effects on meniscus calcification and/or cartilage pathology in female mice and common
marmosets.
So this looks like a negative result from a good quality study. I like that they show every data point, and there’s a lot of biological variability, which looks very realistic and truthful to me. (When I see super tight error bars on papers, I am suspicious). They also do validate that Rapa was hitting the intended targets, suppressing mTOR etc.
What I will say is that it looks to me like the data were affected by a few strong outliers in the Rapamycin group. If you look at Figure 2B and 2D, this is very clear that 4 monkeys had huge calcification whereas 3 had zero. Whether those are some individual “bad responders”, I am not sure.
The marmoset dose (1mg/kg/day) looks incredibly high, which I know has been discussed in detail on this forum, but I don’t think we ever reached a consensus or had an explanation for why this was chosen. Still, the paper is still a sign that Rapa is not protective of OA in this model.